Helicobacter pylori Eradication Therapy Is Effective as the Initial Treatment for Patients with H. pylori -Negative and Disseminated Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
2
조회
0
다운로드
8
인용
0
참고문헌
키워드
초록
Background/Aims: We investigated the effectiveness of Helicobacter pylori eradication therapy for gastric mucosaassociated lymphoid tissue (MALT) lymphoma regardless of the H. pylori infection status or disease stage. Methods: From November 1995 to September 2014, 345 subjects who were diagnosed with gastric MALT lymphoma and had received eradication therapy as their first-line treatment were eligible for inclusion in this study. A retrospective review was performed using the medical records. Results: Of the 345 patients, H. pylori infection was detected in 317 patients (91.9%). The complete remission (CR) rate after eradication therapy was 82.3%, which was higher in H. pylori -positive patients than in H. pylori-negative patients (84.5% vs 57.1%, p=0.001). CR rates after eradication did not present significant differences between stages, and the CR rate was 83.3% for stage IE1 and 74.4% for stage IE2 or above (p=0.167). The overall CR rate was 87.2% after additional treatment, and neither H. pylori infection status nor stage showed differences according to the treatment response. Conclusions: Eradication therapy led to CR in 57.1% of H. pylori-negative patients and in 74.4% of patients with stage IE2 or above. Eradication therapy is worthwhile as an initial treatment for gastric MALT lymphoma regardless of the H. pylori infection status and stage.
Abstract
Background/Aims: We investigated the effectiveness of Helicobacter pylori eradication therapy for gastric mucosaassociated lymphoid tissue (MALT) lymphoma regardless of the H. pylori infection status or disease stage. Methods: From November 1995 to September 2014, 345 subjects who were diagnosed with gastric MALT lymphoma and had received eradication therapy as their first-line treatment were eligible for inclusion in this study. A retrospective review was performed using the medical records. Results: Of the 345 patients, H. pylori infection was detected in 317 patients (91.9%). The complete remission (CR) rate after eradication therapy was 82.3%, which was higher in H. pylori -positive patients than in H. pylori-negative patients (84.5% vs 57.1%, p=0.001). CR rates after eradication did not present significant differences between stages, and the CR rate was 83.3% for stage IE1 and 74.4% for stage IE2 or above (p=0.167). The overall CR rate was 87.2% after additional treatment, and neither H. pylori infection status nor stage showed differences according to the treatment response. Conclusions: Eradication therapy led to CR in 57.1% of H. pylori-negative patients and in 74.4% of patients with stage IE2 or above. Eradication therapy is worthwhile as an initial treatment for gastric MALT lymphoma regardless of the H. pylori infection status and stage.
참고문헌 (25)
- Parsonnet J, "Helicobacter pylori infection and gastric lymphoma", N Engl J Med, 330, pp.1267~1271 (1994)
- Wotherspoon AC, "Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori", Lancet, 342, pp.575~577 (1993)
- Nakamura S, "Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan", Gut, 61, pp.507~553 (2012)
- Zullo A, "Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma", Clin Gastroenterol Hepatol, 8, pp.105~110 (2010)
- Ruskoné-Fourmestraux A, "EGILS consensus report: gastric extranodal marginal zone B-cell lymphoma of MALT", Gut, 60, pp.747~758 (2011)
- Dreyling M, "ESMO Consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma", Ann Oncol, 24, pp.857~877 (2013)
- Raderer M, "Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas", Gut, 55, pp.616~618 (2006)
- Ruskoné-Fourmestraux A, "Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment", Gut, 48, pp.297~303 (2001)
- Zullo A, "Eradication therapy in Helicobacter pylori-negative, gastric low-grade mucosa-associated lymphoid tissue lymphoma patients: a systematic review", J Clin Gastroenterol, 47, pp.824~827 (2013)
- 류광덕, "Treatment Outcome for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma according to Helicobacter pylori Infection Status: A Single- Center Experience", Gut and Liver, 8(4), pp.408~414 (2014), 거트앤리버 발행위원회
- Choi YJ, "Characteristics of Helicobacter pylori-positive and Helicobacter pylori-negative gastric mucosaassociated lymphoid tissue lymphoma and their influence on clinical outcome", Helicobacter, 18, pp.197~205 (2013)
- Raderer M, "Antibiotic treatment as sole management of Helicobacter pylori-negative gastric MALT lymphoma: a single center experience with prolonged follow-up", Ann Hematol, 94, pp.969~973 (2015)
- Cavanna L, "High grade B-cell gastric lymphoma with complete pathologic remission after eradication of Helicobacter pylori infection: report of a case and review of the literature", World J Surg Oncol, 6, pp.35~ (2008)
- Montalban C, "Regression of gastric high grade mucosa associated lymphoid tissue (MALT) lymphoma after Helicobacter pylori eradication", Gut, 49, pp.584~587 (2001)
- Zucca E, "Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 24(6), pp.vi144~vi148 (2013)
- Copie-Bergman C, "Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice", Br J Haematol, 160, pp.47~52 (2013)
- Hong SS, "A prospective analysis of lowgrade gastric malt lymphoma after Helicobacter pylori eradication", Helicobacter, 11, pp.569~573 (2006)
- Wündisch T, "Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication", J Clin Oncol, 23, pp.8018~8024 (2005)
- Fischbach W, "Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series", Gut, 53, pp.34~37 (2004)
- Fischbach W, "Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series", Gut, 56, pp.1685~1687 (2007)
- Yoon Jin Choi, "Low Grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma: Clinicopathological Factors Associated with Helicobacter pylori Eradication and Tumor Regression", Clinical Endoscopy, 44(2), pp.101~108 (2011), 대한소화기내시경학회
- Liu H, "T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication", Gastroenterology, 122, pp.1286~1294 (2002)
- Stathis A, "Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105patients with localized gastric marginal zone B-cell lymphoma of MALT type", Ann Oncol, 20, pp.1086~1093 (2009)
- Raderer M, "High relapse rate in patients with MALT lymphoma warrants lifelong follow-up", Clin Cancer Res, 11, pp.3349~3352 (2005)
- Copie-Bergman C, "Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma?", Ann Oncol, 16, pp.1232~1236 (2005)